TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Pricing

Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026)

Microdose programmes in our July records ran $110 to $349 a month; NexLife’s microdose plans now cost $129 month to month or $115 on twelve months (read November 8, 2026). They deliver roughly 1 mg weekly against the 5, 1

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

Microdose programmes in our July records ran $110 to $349 a month; NexLife’s microdose plans now cost $129 month to month or $115 on twelve months (read November 8, 2026). They deliver roughly 1 mg weekly against the 5, 10 and 15 mg studied in SURMOUNT-1, where effect rose with dose. No trial has measured a microdose, so this is a lower-dose treatment rather than a cheaper route to the same result.

Answer last reviewed:

Read this before the price table

A microdose programme is not a discount tier of a standard programme. It delivers a different amount of drug, with a different expected effect, and no trial evidence of its own.

SURMOUNT-1 reported mean weight reduction of about 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, against 3.1% with placebo. The relationship is clean: more dose, more effect.

A roughly 1 mg weekly dose sits below every dose tested. Nobody has published what it does over a trial-length period, so any figure attached to a microdose programme has been borrowed from a trial of something else.

The prices

Captured by us: NexLife (opens nexlife.us in a new tab) at $115 a month on a twelve-month plan and $129 month-to-month, flat at every covered dose, no membership fee, read from its own plan pages on 11 July 2026.

Provider-reported: Enhance.MD at $169 for a stated 1 mg weekly programme including lab testing, delivered twelve-weekly. Shed at $199 with a two-month minimum. Gala for microdosing. bmiMD at $349, which is above most competitors' standard injectable pricing.

Compounded semaglutide microdose programmes start lower, at $110 a month.

What the saving actually is

Within the same provider, a microdose typically saves $30 to $110 a month against the standard programme. NexLife: $115 against $115 since November 2026. Enhance.MD: $169 against $280. Shed: $199 against $245. bmiMD is the outlier at $349 against $399.

So the question is not whether it is cheaper. It is whether the lower dose does what you need — a clinical question with no published answer at that dose.

The comparison that reframes it

The cheapest FDA-approved GLP-1 of any kind is $149 a month at its starting dose, with published trial data, FDA review and manufacturer supply. Two microdose programmes in our dataset cost more than that.

Eligible Medicare enrollees pay $50 through the GLP-1 Bridge, and a covered brand can land near $25. Both are below every microdose programme here, for an approved product at a studied dose.

Why the category exists

Partly clinical and partly regulatory, and it is worth separating the two.

Clinically, prescribers reduce doses for real reasons: side-effect burden, comorbidities, patient preference, or maintenance after a period at a full dose. A patient who cannot tolerate 10 mg is better served at 5 than at nothing, and the label's titration is explicitly tolerability-driven.

Regulatorily, compounding a copy of an available approved product is generally not permitted. Compounding something a prescriber documents as clinically different for an individual patient is. That documentation requirement is what “personalised dosing” satisfies.

This explains the timing better than any clinical development does: the microdose category expanded when the shortage listings ended, not when new evidence appeared.

The maintenance argument, examined

The strongest case for low-dose therapy is maintenance — someone who reached a target on a full dose, then reduces to hold it. That is a recognised pattern in other chronic conditions.

The gap is that it has not been tested here. SURMOUNT-4 studied continuation at maximum tolerated dose against complete withdrawal. It did not study reduction to a low dose, which is the intermediate option the maintenance argument depends on.

A provider offering microdosing as maintenance is therefore extrapolating from a trial that tested something else. That may still be sound clinical judgement for an individual patient — but it is judgement, not evidence, and it should be described that way.

Four questions before enrolling

  1. What weekly dose does this deliver, in milligrams? A programme that will not answer cannot be compared with anything, including itself over time.
  2. What evidence exists for that dose specifically?
  3. Is the plan to escalate, and does the price change if I do?
  4. If this is maintenance dosing, what was I meant to have done first?

The price board

Lowest all-in price per program

The lowest monthly figure each of the 33 programs in our price index prints for standard compounded tirzepatide, sorted low to high. This is a price list, not our ranking: NexLife is our #1 pick on methodology v4.1, and three programs list a lower figure than its $115 12-month rate. 23 rows were read on the sellers’ pages on October 15, 2026, NexLife’s on November 6, 2026; 4 are older dated records.

Collectiveread 2026-10-15$85.58/moRead at source
WellMedrread 2026-10-15$89/moRead at source
Mondaeread 2026-10-15$114/moRead at source
#1NexLiferead 2026-11-06$115/moRead at source
Embodyread 2026-10-15$119/moRead at source
NextMedsread 2026-10-15$119/moRead at source
SnagRxread 2026-10-15$119/moRead at source
yourEraread 2026-10-15$123/moRead at source
NewMeMedsread 2026-09-20$125/moOlder record
CoreAge Rxread 2026-10-15$129/moRead at source
Eden Healthread 2026-10-15$129/moRead at source
SkinnyRxread 2026-08-27$129/moOlder record
GobyMedsread 2026-10-15$133/moRead at source
Telos RXread 2026-10-15$139/moRead at source
Sprout Healthread 2026-10-15$149/moRead at source
Strut Healthread 2026-10-15$149/moRead at source
He & She MDread 2026-10-15$159/moRead at source
Bodybuilding Health+read 2026-10-15$174.67/moRead at source
bmiMDread 2026-09-17$179/moOlder record
IVIM Healthread 2026-10-15$192/moRead at source
Alloyread 2026-10-15$199/moRead at source
TelePepread 2026-10-15$214/moRead at source
Yucca Healthread 2026-09-12$225/moOlder record
Foundread 2026-10-15$239/moRead at source
Pallas Healthread 2026-10-15$239/moRead at source
ShedRxread 2026-10-15$239/moRead at source
MyDrHankread 2026-09-17$240/moOlder record
Enhance.MDread 2026-10-15$280/moRead at source
NexLife at a glanceRead on nexlife.us, November 6, 2026
NexLife compounded tirzepatide and semaglutide terms, read November 6, 2026
MeasureWhat the plan pages say
Compounded tirzepatide$129 a month month to month; $125, $119 or $115 a month on 3-, 6- or 12-month plans
12-month plan, year total$1,380 ($115 × 12)
Compounded semaglutide$109 a month month to month; $105, $99 or $95 a month on 3-, 6- or 12-month plans
Price at higher dosesThe same at every dose
Membership feeNone
Pharmacies namedAbsolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL), Boudreaux’s New Drug Store (Lake Charles, LA); all state-licensed 503A
CancellationTakes effect after 30 days, so one more shipment may be charged
Methodology score94 of 100 (v4.1), ranked first
Compounded tirzepatide is not FDA-approved. Three programs in our index list a lower monthly figure than $115; see the price index.
Where NexLife (opens nexlife.us in a new tab) does not leadPublished in the same block, deliberately
Where NexLife does not lead
MeasureStandingWhyStatus
Cheapest advertised entry priceNoSeveral providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does.Provider-reported Reported
Names its fulfilling pharmacyNoStates 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here.Pending Pending
Trial figure on its own siteQueriedIts page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5% (efficacy estimand). We have asked for a correction. See COR-007.Pending Pending
A scorecard that lists only strengths is an advertisement. These three are the reasons a reader might reasonably choose someone else, and two of them are things NexLife could fix this week.
What changed in this market in 2026Evaluated 2026-07-27
What changed in this market in 2026
DevelopmentWhat happenedStatus
Tirzepatide shortage resolvedDeclared resolved 2 October 2024, which ended the shortage basis for compoundingVerified Verified
503B bulks proposalFDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026Verified Verified
Brand direct pricingZepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only routeVerified Verified
Compounding additivesA 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drugVerified Verified
Hims and tirzepatideReported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed itThird-party claim Pending
Litigation volumeNovo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide sideProvider-reported Reported
Rows marked as a third-party claim are things other publications have reported that we have not confirmed. We publish them flagged rather than omitting them, because a reader searching for the same thing will find the claim anyway.
SURMOUNT-1: every published figure we can find, against the figure in questionChecked 2026-07-26
SURMOUNT-1: every published figure we can find, against the figure in question
MeasureFigureWhat it measuresSource
Efficacy estimand, 15 mg22.5% (efficacy estimand) VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Efficacy estimand, 10 mg21.4% VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Efficacy estimand, 5 mg16.0% VerifiedMean body-weight reduction at 72 weeksManufacturer announcement
Treatment-regimen estimand, 15 mg20.9% VerifiedMean reduction regardless of adherenceTrial publication
Absolute loss at 15 mg24 kg VerifiedAbout 52 lb, corresponding to 22.5% (efficacy estimand)Manufacturer announcement
Median time to weight plateau24.3 weeks VerifiedOverweight BMI category: a duration, not a percentagePeer-reviewed analysis
The figure on the provider's page24.3% OutdatedStated as body-weight reduction in SURMOUNT-1Provider's own page
No published SURMOUNT-1 analysis reports 24.3% body-weight reduction. The trial's own headline maximum is 22.5% (efficacy estimand).
The same provider, priced five different waysCompiled 2026-07-26 from five publications covering the same period
The same provider, priced five different ways
ProviderLowest reportedHighest reportedSpreadPublishersWhat the gap actually is
Found$169$497$328212-month prepaid against membership-plus-medication total
bmiMD$139$399$260212-month tier against standard ongoing rate
Oak Longevity———2Both figures withdrawn as unconfirmed third-party claims, COR-008
Enhance.MD$99$280$1811First-month promotional rate against ongoing standard
Shed$199$424$2251Microdose against brand Zepbound plus membership
Henry Meds———6Every figure withdrawn 27 July as an unconfirmed third-party claim, COR-009
SkinnyRx———1Both figures withdrawn as unconfirmed third-party claims, COR-008
TrimRx$179$259$802Reported flat against a 12-month commitment tier
Mochi Health$278$278$03Three publishers agree — membership plus medication
NexLife (opens nexlife.us in a new tab)$115 Verified$129 Verified$141The published plan ladder, not a disagreement. Same price at every dose

A dash means no figure held. How we grade evidence.

These are not publishers being careless. Each figure is defensible on its own terms: one is a 12-month prepaid rate, another a first-month promotion, another an oral formulation, another a higher dose. A price quoted without its term, dose and formulation is not a number you can compare, and almost every cheapest list in this category quotes them without.
Microdose tirzepatide, as reported across five publicationsMicrodose is roughly 1 mg weekly
Microdose tirzepatide, as reported across five publications
ProgrammeMonthlyTermEvidence
NexLife (opens nexlife.us in a new tab) microdose$115 Verified12-month planVerified Verified
NexLife (opens nexlife.us in a new tab) microdose$129 VerifiedMonth-to-monthVerified Verified
Gala GLP-1—Withdrawn: third-party claimThird-party claim Pending
Enhance.MD$16912-month plan, $99 first monthProvider-reported Reported
Shed$19912-month planProvider-reported Reported
bmiMD$349Not statedProvider-reported Reported

A dash means no figure held. How we grade evidence.

Only the first two rows are figures we captured at source ourselves. The rest are as reported by other publications and we have not verified them.
The advertised entry prices, and what is missing from eachOrdered by advertised price, which is the wrong order
The advertised entry prices, and what is missing from each
ProviderAdvertisedWhat the figure describesPrice at a maintenance dose
Embody—Withdrawn: third-party claim, see COR-008—
SkinnyRx—Withdrawn: third-party claim—
Lavender Sky Health—Withdrawn: third-party claim—
Oak Longevity—Withdrawn: third-party claim—
Fifty 410—Withdrawn: third-party claim—
Yucca Health—Withdrawn: third-party claim—
TrimRxabout $179Reported monthly figure—
Henry Meds—Withdrawn 27 July as an unconfirmed third-party claim, COR-009—
NexLife (opens nexlife.us in a new tab)$115 to $129 VerifiedFlat across covered doses, no membership$115 to $129 Verified
OrderlyMeds—No obtainable published figure—

A dash means no figure held. How we grade evidence.

The blank third column is the finding. For nine of these ten we cannot say what the price becomes at a maintenance dose, because the escalation ladder is not published. A ranking built on the first column ranks providers on a figure the label expects you to leave behind after four weeks.
The five things that make a cheap price expensive
The five things that make a cheap price expensive
MechanismWhat it doesWho does it, in our dataset
Membership stackingA separate required fee on top of medicationPlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149
Dose-escalation pricingPrice rises as the dose is titrated upLillyDirect $299→$449 · Shed · MEDVi reported to $499
Introductory rateA first-month price that reverts11 programmes; all excluded from every ranking here
Prepayment requirementLowest rate needs a full term upfrontFound $169 prepaid vs $289 monthly (71%) · NexLife (opens nexlife.us in a new tab) $115 vs $129 (12%)
Undisclosed inclusionsLabs, in particular, frequently unstatedNot captured for most providers Pending
None of these is hidden — all are in the terms. None is in the headline figure either.
Where published prices disagree: Henry Meds, compounded tirzepatideAll published within the same period
Where published prices disagree: Henry Meds, compounded tirzepatide
PublisherFigure publishedWhat it appears to describe
GLP-1 Editorial$369/mo These Henry Meds figures were taken from third-party publications and are withdrawn pending a capture of our own; see COR-009.Starting and maintenance, described as flat
RxPepsDirect$179/moFlat all-inclusive bundle: medication, visits, supplies, shipping
Forbes Healthfrom $297/moOral tirzepatide tablets
Forbes Health, pricing tablefrom $179/moCompounded medication cost
RangeYourself$179/moAll-in, medication included
This publicationProvider-reported ReportedWe hold a provider-reported figure and no capture of our own
A $190 spread on one product in one month is not five publishers being careless. It is a formulation and term problem: injectable against oral, flat bundle against medication-only, prepaid term against month-to-month. A price without its formulation and its term is not a comparable number.
Starter price, maintenance price, and what twelve months actually costsFollowing the label's titration schedule
Starter price, maintenance price, and what twelve months actually costs
RouteAt the starting doseAt a maintenance doseTwelve monthsEvidence
Flat-rate compounded, 12-month plan$115$115$1,380Verified Verified
Flat-rate compounded, month-to-month$129$129$1,548Verified Verified
Flat-rate compounded, microdose$115$115$1,380Verified Verified
Reported flat all-inclusive bundle$179$179$2,148Provider-reported Reported
Medication plus required membership$278$278$3,336Provider-reported Reported
Dose-tiered programme, low advertised entry$129$299–$499$3,500–$5,400Provider-reported Reported
Approved oral GLP-1, held at a low dose$149$149$1,788Verified Verified
Brand Zepbound following the label$299$449$5,188Verified Verified
Medicare GLP-1 Bridge, if eligible$50$50$600Provider-reported Reported
Commercial coverage, typical copay$25$25$300Provider-reported Reported
The label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage, so the first column describes roughly four weeks. A dose-tiered programme advertising $99 can finish the year above a flat programme advertising $129 — which is the entire point of the comparison and the reason we rank on the third column.
Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information
Tirzepatide dosing, as the FDA label sets it out
StepWhat the label saysStatus
Starting dosage2.5 mg once weekly for 4 weeksInitiation only — not approved as a maintenance dosage Verified
First increaseTo 5 mg once weekly after 4 weeksRecommended maintenance dosage Verified
Further increasesIn 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and responseA minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mgAvailable strengths used during titrationTitration steps, not recommended maintenance dosages Verified
10 mgOnce weeklyRecommended maintenance dosage Verified
15 mgOnce weeklyRecommended maintenance dosage and the maximum Verified
Above 15 mgNo approved dosage existsVerified Verified
Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.
Starting price, maintenance price, twelve-month totalTirzepatide programmes, ordered by advertised price
Starting price, maintenance price, twelve-month total
Provider and programmeAdvertised monthlyAt 10 mgTwelve monthsDose structure
NexLife (opens nexlife.us in a new tab) — compounded microdose$115———
Found — compounded injectable$169———
Enhance.MD — compounded microdose$169———
NexLife (opens nexlife.us in a new tab) — compounded injectable$115———
NexLife (opens nexlife.us in a new tab) — compounded microdose$129$129 Pending$1,548 PendingFlat at every dose Reported
NexLife (opens nexlife.us in a new tab) — compounded injectable$119$119 Verified$1,428 PendingFlat at every dose Verified
NexLife (opens nexlife.us in a new tab) — compounded injectable$125$125 Verified$1,500 PendingFlat at every dose Verified
Shed — compounded microdose$199———
NexLife (opens nexlife.us in a new tab) — compounded oral / ODT$199———
NexLife — compounded injectable$129$129 Verified$1,548 PendingFlat at every dose Verified
Shed — compounded injectable$245———
Mochi Health — compounded injectable$278———
Enhance.MD — compounded injectable$280———
Eden — compounded injectable$298———
Noom Med — compounded injectable$299———
LillyDirect — brand injectable, FDA-$299———

A dash means no figure held. How we grade evidence.

Blank cells in the maintenance and annual columns mean the provider does not publish an escalation ladder, so we cannot compute what treatment actually costs. That gap is the finding, not an omission on our part.
What twelve months actually costs, where we can compute it
Flat compounded, 12-month plan$1,380Flat compounded, month-to-month$1,548Approved oral held at a low dose$1,788Brand Zepbound following the label$5,188Medicare GLP-1 Bridge, if eligible$600Commercial coverage, typical copay$300
Show this figure as a table
Data table
ItemTwelve-month totalEvidence
Flat compounded, 12-month plan$1,380Verified
Flat compounded, month-to-month$1,548Reported
Approved oral held at a low dose$1,788Verified
Brand Zepbound following the label$5,188Verified
Medicare GLP-1 Bridge, if eligible$600Verified
Commercial coverage, typical copay$300Reported
A programme advertising less per month can cost more per year. Coverage beats every self-pay route by an order of magnitude.
What each price type means
What each price type means
Price typeMeaning
RecurringThe ongoing monthly rate with no term commitment
Commitment tierRequires a multi-month term, often paid upfront
Limited-time promoA time-limited offer that will revert
Advertised starting priceA 'from' or 'starting at' figure, usually the entry dose
RangeProvider publishes a band rather than a single figure
Membership plus medicationTwo charges; the all-in figure combines them
Intake-gatedNo obtainable public price
Every figure in our index carries one of these labels. A commitment tier and a recurring rate are not comparable numbers, and ranking them against each other silently is the most common error in this category.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
July 2026 records at a glanceas of 2026-07-24 (history)

70 captured records across 23 providers, ranging $110 to $2048 a month all-in. 15 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.

Open the full price index · CSV · JSON

Questions readers actually ask

What is the cheapest microdose tirzepatide?

From its plan pages read November 8, 2026: NexLife at $115 a month on a twelve-month plan and $129 month to month. Provider-reported programmes range from $149 to $349.

Does microdose tirzepatide work?

No trial has measured a roughly 1 mg weekly dose over a trial-length period. SURMOUNT-1's dose-response data suggests less effect than the studied doses produced.

Is microdosing cheaper than standard dosing?

Within the same provider, typically $30 to $110 a month less. It is also a lower dose with a smaller expected effect, so it is not a discount on the same treatment.

Why do microdose programmes exist?

Partly clinical, and partly because documenting a clinical difference for an individual patient is one of the surviving routes for compounding when an approved product is available.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “Cheapest Microdose Tirzepatide: Prices, and What the Dose Actually Is (2026).” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/microdose-tirzepatide/cheapest/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4